The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Subscribe To Our Newsletter & Stay Updated
